AKC Canine Health Foundation Alerts
AKC Call for Participation [August 29, 2007] -- See complete article.
Studying heart
function in dogs with lymphoma -- All Breeds
A new Veterinary Teaching Hospital study is being conducted to determine
whether doxorubicin, one of the primary drugs used in treating lymphoma in
dogs, may weaken the canine heart.
Please e-mail
julie_osborne@ncsu.edu for more information.
Understanding genetic role in treating epileptic seizures -- Rough and Smooth-coated
Collies, Shetland Sheepdogs, and Australian Shepherds
Some 5% of all dogs experience seizures and, while medication can be an
effective cornerstone of treatment for two-thirds of dogs who suffer from
primary idiopathic epilepsy, one-third of the affected dogs do not respond
to treatment with seizure medications.
Dr. Karen Munana, associate professor of neurology, is collaborating with
Dr. Katrina Mealey of Washington State University to examine how genetics
may play a role in why some epileptic dogs respond poorly to traditional
treatment.
For more information, e-mail
julie_osborne@ncsu.edu,
animalepilepsy@ncsu.edu or visit
this site.
Recruitment of
Epileptic Dogs for Seizure Drug Study Continues -- All Breeds
The clinical trial demonstrating the possible effectiveness of the
pharmaceutical drug Keppra as an additional therapy in the treatment of
canine epilepsy aims to recruit 10-15 more dogs to complete this important
study in canine epilepsy. Dr. Karen Munana, principal investigator of the
study notes that initial results demonstrate that this drug may be effective
controlling seizures in some dogs with epilepsy. By adding 10-15 more dogs
to this study base, statistical summaries will provide additional
information to firm up this claim. The study is multi-institutional study,
with veterinary neurologists from North Carolina State University, the
University of Tennessee, and Virginia-Maryland College of Veterinary
Medicine participating.
If additional information is needed for interested referring veterinarians
and/or owners please contact study research technician,
julie_osborne@ncsu.edu, or fax inquiries to 919-513-6830. More
information regarding this study can also be found
here.
Dogs with Oral
Melanoma -- All Breeds
Dogs with oral melanoma are being recruited for a study of a novel vaccine
developed by Merial Limited, an animal pharmaceutical company, to determine
if this vaccine can help to prolong the survival time in dogs with oral
melanoma. Dogs enrolled in the study will receive the melanoma vaccine and
associated exams and labwork and radiographs which will be subsidized by the
study.
For more information on this study email:
paul_hess@ncsu.edu or
julie_osborne@ncsu.edu or call 919-513-6812.
See more details of all four studies.
Contribute to this and other education programs funded by the AKC Canine Health Foundation.
Contact:
Jeff Sossamon
Director of Development & Communications
AKC Canine Health Foundation
PO Box 37941
Raleigh, NC 27627-7941
(919) 334-4015 (b)
(919) 334-4011 (f)
(888) 682-9696 (toll free)
jds@akcchf.org
www.akcchf.org